切换导航
  • 比较产品
我的购物车

若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

EasySep™人B细胞富集试剂盒II（不去除CD43）

免疫磁珠负选试剂盒
率先评论此产品
添加并比较

产品号 #（选择产品）

产品号 #17963_C

免疫磁珠负选试剂盒

产品优势

  • 操作简单、快捷
  • 纯度高达99%
  • 分选得到的细胞不带标记

产品组分包括

  • EasySep™人B细胞富集试剂盒II（不去除CD43） (产品号 #17963)    
    • EasySep™人B细胞富集抗体混合物（不去除CD43）, 1 mL
    • EasySep™人分选抗体混合物增强剂, 1 mL    
    • EasySep™ Dextran RapidSpheres™ 50102磁珠, 1 mL
  • RoboSep™人B细胞富集试剂盒II（不去除CD43） (产品号 #17963RF)    
    • EasySep™人B细胞富集抗体混合物（不去除CD43）, 1 mL
    • EasySep™人分选抗体混合物增强剂, 1 mL    
    • EasySep™ Dextran RapidSpheres™ 50102磁珠, 1 mL
    • RoboSep™ 缓冲液（产品号 #20104）
    • RoboSep™过滤吸头（产品号 #20125）
main product photo
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
专为您的实验方案打造的产品
要查看实验方案所需的所有配套产品，请参阅《实验方案与技术文档》。
  1. EasySep™ Magnet
    EasySep™ Magnet

    Magnet for column-free immunomagnetic separation

  2. EasySep™ Buffer
    EasySep™ Buffer

    Cell separation buffer

总览
实验数据
产品说明书及文档
应用领域
相关材料与文献
相关产品

总览

EasySep™ 人B细胞富集试剂盒II（不去除 CD43）从B细胞白血病或淋巴瘤或其他B细胞可能表达CD43的疾病患者新鲜或冻存的外周血单个核细胞（PBMCs）中负选B细胞。EasySep™操作流程包括通过抗体复合物和磁珠标记非目的细胞。通过EasySep™磁极将被磁珠标记的细胞与未被标记的目的细胞分离，目的细胞倾倒或移液吸取至新试管中。

该试剂盒可替代EasySep™人B细胞富集试剂盒（不去除CD43） (产品号 #19154) 以实现更快速地细胞分选。

该试剂盒可替代EasySep™人B细胞富集试剂盒（不去除CD43） (产品号 #19154) 以实现更快速地细胞分选。

该试剂盒可替代EasySep™人B细胞富集试剂盒（不去除CD43） (产品号 #19154) 以实现更快速地细胞分选。

该试剂盒可替代EasySep™人B细胞富集试剂盒（不去除CD43） (产品号 #19154) 以实现更快速地细胞分选。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
 
亚型
细胞分选试剂盒
 
细胞类型
B 细胞
 
种属
人
 
样本来源
PBMC
 
筛选方法
Negative
 
应用
细胞分选
 
品牌
EasySep，RoboSep
 
研究领域
免疫
 

查看更多 显示更少

实验数据

Starting with fresh PBMCs, the B cell content (CD19+) of the enriched fraction is typically 84.9 ± 13.9% (mean ± SD using the purple EasySep™ Magnet). In the above example, the purities of the start and final enriched fractions are 14.8% and 85.8%, respectively.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
EasySep™ Human B Cell Enrichment Kit II Without CD43 Depletion
Catalog #
17963
Lot #
All
Language
English
Document Type
Product Information Sheet
Product Name
RoboSep™ Human B Cell Enrichment Kit II without CD43 Depletion
Catalog #
17963RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
EasySep™ Human B Cell Enrichment Kit II Without CD43 Depletion
Catalog #
17963
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
EasySep™ Human B Cell Enrichment Kit II Without CD43 Depletion
Catalog #
17963
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Product Name
EasySep™ Human B Cell Enrichment Kit II Without CD43 Depletion
Catalog #
17963
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
RoboSep™ Human B Cell Enrichment Kit II without CD43 Depletion
Catalog #
17963RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
RoboSep™ Human B Cell Enrichment Kit II without CD43 Depletion
Catalog #
17963RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Product Name
RoboSep™ Human B Cell Enrichment Kit II without CD43 Depletion
Catalog #
17963RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Product Name
RoboSep™ Human B Cell Enrichment Kit II without CD43 Depletion
Catalog #
17963RF
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area
Workflow Stages

相关材料与文献

技术资料 (8)

Human B Cell Isolation Product Selection
Brochure
Human B Cell Isolation Product Selection
EasySep™ Cell Separation Technology
Brochure
EasySep™ Cell Separation Technology
Antigen Processing and Presentation
Wallchart
Antigen Processing and Presentation
Human Immune Cytokines
Wallchart
Human Immune Cytokines
Frequencies of Human Cell Types in Blood-Related Sources
Wallchart
Frequencies of Human Cell Types in Blood-Related Sources
How to Isolate PBMCs from Whole Blood Using Density Gradient Centrifugation (Ficoll™ or Lymphoprep™)
1:37
Video
How to Isolate PBMCs from Whole Blood Using Density Gradient Centrifugation (Ficoll™ or Lymphoprep...
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology
1:13
Video
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
1:57
Video
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation

文献 (5)

Cytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients. V. O. Boldrini et al. Frontiers in immunology 2022

Abstract

BACKGROUND Emerging evidence of antibody-independent functions, as well as the clinical efficacy of anti-CD20 depleting therapies, helped to reassess the contribution of B cells during multiple sclerosis (MS) pathogenesis. OBJECTIVE To investigate whether CD19+ B cells may share expression of the serine-protease granzyme-B (GzmB), resembling classical cytotoxic CD8+ T lymphocytes, in the peripheral blood from relapsing-remitting MS (RRMS) patients. METHODS In this study, 104 RRMS patients during different treatments and 58 healthy donors were included. CD8, CD19, Runx3, and GzmB expression was assessed by flow cytometry analyses. RESULTS RRMS patients during fingolimod (FTY) and natalizumab (NTZ) treatment showed increased percentage of circulating CD8+GzmB+ T lymphocytes when compared to healthy volunteers. An increase in circulating CD19+GzmB+ B cells was observed in RRMS patients during FTY and NTZ therapies when compared to glatiramer (GA), untreated RRMS patients, and healthy donors but not when compared to interferon-$\beta$ (IFN). Moreover, regarding Runx3, the transcriptional factor classically associated with cytotoxicity in CD8+ T lymphocytes, the expression of GzmB was significantly higher in CD19+Runx3+-expressing B cells when compared to CD19+Runx3- counterparts in RRMS patients. CONCLUSIONS CD19+ B cells may exhibit cytotoxic behavior resembling CD8+ T lymphocytes in MS patients during different treatments. In the future, monitoring cytotoxic" subsets might become an accessible marker for investigating MS pathophysiology and even for the development of new therapeutic interventions."
View publication
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. M. J. Frank et al. The Journal of experimental medicine 2020 sep

Abstract

Here, we report on the results of a phase I/II trial (NCT00490529) for patients with mantle cell lymphoma who, having achieved remission after immunochemotherapy, were vaccinated with irradiated, CpG-activated tumor cells. Subsequently, vaccine-primed lymphocytes were collected and reinfused after a standard autologous stem cell transplantation (ASCT). The primary endpoint was detection of minimal residual disease (MRD) within 1 yr after ASCT at the previously validated threshold of ≥1 malignant cell per 10,000 leukocyte equivalents. Of 45 evaluable patients, 40 (89{\%}) were found to be MRD negative, and the MRD-positive patients experienced early subsequent relapse. The vaccination induced antitumor CD8 T cell immune responses in 40{\%} of patients, and these were associated with favorable clinical outcomes. Patients with high tumor PD-L1 expression after in vitro exposure to CpG had inferior outcomes. Vaccination with CpG-stimulated autologous tumor cells followed by the adoptive transfer of vaccine-primed lymphocytes after ASCT is feasible and safe.
View publication
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients. P. Monti et al. Scientific reports 2020

Abstract

Chronic lymphocytic leukaemia (CLL) is characterised by a heterogeneous clinical course. Such heterogeneity is associated with a number of markers, including TP53 gene inactivation. While TP53 gene alterations determine resistance to chemotherapy, it is not clear whether they can influence early disease progression. To clarify this issue, TP53 mutations and deletions of the corresponding locus [del(17p)] were evaluated in 469 cases from the O-CLL1 observational study that recruited a cohort of clinically and molecularly characterised Binet stage A patients. Twenty-four cases harboured somatic TP53 mutations [accompanied by del(17p) in 9 cases], 2 patients had del(17p) only, and 5 patients had TP53 germ-line variants. While del(17p) with or without TP53 mutations was capable of significantly predicting the time to first treatment, a reliable measure of disease progression, TP53 mutations were not. This was true for cases with high or low variant allele frequency. The lack of predictive ability was independent of the functional features of the mutant P53 protein in terms of transactivation and dominant negative potential. TP53 mutations alone were more frequent in patients with mutated IGHV genes, whereas del(17p) was associated with the presence of adverse prognostic factors, including CD38 positivity, unmutated-IGHV gene status, and NOTCH1 mutations.
View publication
View All Publications

更多信息

更多信息
种属 Human
Magnet Compatibility • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
样本来源 PBMC
Selection Method Negative
标记抗体
  1. 抗人CD20抗体，克隆2H7
    抗人CD20抗体，克隆2H7

    小鼠单克隆IgG2b抗体，抗人、恒河猴、食蟹猴CD20

  2. 抗人CD19抗体，克隆HIB19
    抗人CD19抗体，克隆HIB19

    抗人、黑猩猩CD19的小鼠单克隆IgG1抗体

质量保证:

产品仅供研究使用，不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息，请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.